A
Ayman El-Kattan
Researcher at Pfizer
Publications - 69
Citations - 4364
Ayman El-Kattan is an academic researcher from Pfizer. The author has contributed to research in topics: Pharmacokinetics & Bioavailability. The author has an hindex of 34, co-authored 69 publications receiving 3825 citations. Previous affiliations of Ayman El-Kattan include University of South Carolina.
Papers
More filters
Journal ArticleDOI
Physicochemical determinants of human renal clearance.
Manthena V.S. Varma,Bo Feng,R. Scott Obach,Matthew D. Troutman,Jonathan Chupka,Howard Miller,Ayman El-Kattan +6 more
TL;DR: In conclusion, ionization state, lipophilicity, and polar descriptors are found to be the physicochemical determinants of renal clearance.
Journal ArticleDOI
The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities.
TL;DR: The four terpene enhancers produced linear relationships, indicating that they were more effective at enhancing the penetration of hydrophilic drugs rather than lipophilic drugs.
Journal ArticleDOI
The road map to oral bioavailability: an industrial perspective
V. Hayden Thomas,Shobha N. Bhattachar,Linda Hitchingham,Philip Zocharski,Maryanne Naath,Narayanan Surendran,Chad L. Stoner,Ayman El-Kattan +7 more
TL;DR: A team-based discussion tool is proposed that provides a road map to guide the selection of profiling assays that should be considered when optimising oral bioavailability and divides the factors that contribute to poor oral bio availability into two interrelated categories: absorption and metabolism.
Journal ArticleDOI
How modeling and simulation have enhanced decision making in new drug development
Raymond Miller,Wayne Ewy,Brian Corrigan,Daniele Ouellet,David Hermann,Kenneth G. Kowalski,Peter Lockwood,Jeffrey R. Koup,Sean D. Donevan,Ayman El-Kattan,Cheryl Li,John L. Werth,Douglas Feltner,Richard L. Lalonde +13 more
TL;DR: The idea of model-based drug development championed by Lewis Sheiner, in which pharmacostatistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers a quantitative approach to improving drug development and development decision-making.
Journal ArticleDOI
pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Manthena V.S. Varma,Iain Gardner,Stefanus J. Steyn,Paul Nkansah,Charles J. Rotter,Carrie Whitney-Pickett,Hui Zhang,Li Di,Michael Cram,Katherine S. Fenner,Ayman El-Kattan +10 more
TL;DR: P pH-dependent permeability and solubility criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process are identified.